Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for VTE Prevention in Multiple Myeloma
NCT02958969Phase 4Completed
- Start
- Feb 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apixaban in venous thromboembolism (VTE). Primary endpoints: Frequency of Symptomatic Venous Thromboembolism at 6 months and Frequency of Major and Clinically Relevant Non-major Bleeding at 6 months. Started Feb 2018; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02958969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958969.